Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients

Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Bernice Ling Zhi, Tan, Nicole, de Alwis, Ruklanthi, Kunasegaran, Kamini, Chen, Zhiwei, Poon, Michelle, Chan, Esther, Low, Jenny G. H., Yeoh, Allen Eng Juh, Bertoletti, Antonio, Le Bert, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Letters to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/
https://www.ncbi.nlm.nih.gov/pubmed/35472242
http://dx.doi.org/10.1182/blood.2022016166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281508/
https://www.ncbi.nlm.nih.gov/pubmed/35472242
http://dx.doi.org/10.1182/blood.2022016166

Ejemplares similares